Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial

Circulation. 2020 Feb 4;141(5):407-410. doi: 10.1161/CIRCULATIONAHA.119.044359. Epub 2019 Nov 11.
No abstract available

Keywords: SGLT2 inhibitors; canagliflozin; chronic kidney disease; diabetes mellitus, type 2.

Publication types

  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Canagliflozin / pharmacology*
  • Cardiovascular System / drug effects
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Female
  • Glycated Hemoglobin A / metabolism*
  • Humans
  • Hypoglycemic Agents / pharmacology
  • Kidney / drug effects
  • Male
  • Renal Insufficiency, Chronic / complications
  • Renal Insufficiency, Chronic / drug therapy*

Substances

  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Canagliflozin

Associated data

  • ClinicalTrials.gov/NCT02065791